Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

699 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F. Rossignol P, et al. Circ Heart Fail. 2014 Jan;7(1):51-8. doi: 10.1161/CIRCHEARTFAILURE.113.000792. Epub 2013 Dec 2. Circ Heart Fail. 2014. PMID: 24297687 Clinical Trial.
Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
Vardeny O, Claggett B, Anand I, Rossignol P, Desai AS, Zannad F, Pitt B, Solomon SD; Randomized Aldactone Evaluation Study (RALES) Investigators. Vardeny O, et al. Among authors: rossignol p. Circ Heart Fail. 2014 Jul;7(4):573-9. doi: 10.1161/CIRCHEARTFAILURE.114.001104. Epub 2014 May 8. Circ Heart Fail. 2014. PMID: 24812304 Clinical Trial.
Fibrinolysis for intermediate-risk pulmonary embolism.
Girerd N, Rossignol P, Zannad F. Girerd N, et al. Among authors: rossignol p. N Engl J Med. 2014 Aug 7;371(6):579. doi: 10.1056/NEJMc1406283. N Engl J Med. 2014. PMID: 25099592 Free article. No abstract available.
Time to retrieve the best benefits from renin angiotensin aldosterone system (RAAS) inhibition in heart failure patients with reduced ejection fraction: lessons from randomized controlled trials and registries.
Rossignol P, Zannad F, Pitt B; Writing group of 10th Global Cardio Vascular Clinical Trialist forum held on December 6th-7th 2013 in Paris, France. Rossignol P, et al. Int J Cardiol. 2014 Dec 20;177(3):731-3. doi: 10.1016/j.ijcard.2014.11.004. Epub 2014 Nov 5. Int J Cardiol. 2014. PMID: 25465821 Review.
Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials.
Rossignol P, Masson S, Barlera S, Girerd N, Castelnovo A, Zannad F, Clemenza F, Tognoni G, Anand IS, Cohn JN, Anker SD, Tavazzi L, Latini R; GISSI-HF and Val-HeFT Investigators. Rossignol P, et al. Eur J Heart Fail. 2015 Apr;17(4):424-33. doi: 10.1002/ejhf.240. Epub 2015 Feb 22. Eur J Heart Fail. 2015. PMID: 25704364 Free article.
699 results